Overall, chromatin‐based epigenetic modifications are key drivers of metastatic prostate cancer, contributing to aggressive phenotypes by promoting JAK–STAT signaling and EMT, as well as enabling cancer cells to adopt immune‐like characteristics. This evidence concerns the gene SOAT1 and prostate carcinoma.